Epigenetic alterations in mantle cell lymphoma

ESH eLearning, José Ignacio, 349645

Role of epigenetic aberrations in DLBCL

ESH eLearning, Ari Melnick, 349644

Panel Discussion

ESH eLearning, Faculty / Presenters, 349643

Selected brief oral communication: Outcome Prediction in CLL By Integration of Serial MRD: The Refined Continuous Individualized Risk Index (CIRI2-CLL)

ESH eLearning, Othman Al-Sawaf, 349642

Targeting genetic alterations in lymphoma

ESH eLearning, Andrew Davies, 349641

The genetic landscape of mantle cell lymphoma

ESH eLearning, Elias Campo, 349640

Panel Discussion

ESH eLearning, Faculty / Presenters, 349639

Selected brief oral communication: The Alternative RelB NFkB Subunit Is a Novel Critical Player in Diffuse Large B-Cell Lymphoma

ESH eLearning, Véronique Baud, 349638

Dissecting GCB DLBCL and its therapeutic implications

ESH eLearning, David Scott, 349637

Incidence of Pleural Effusion with Dasatinib and the Effect of Switching Therapy to Bosutinib in Patients with Chronic Phase CML

ESH eLearning, Akriti Jain, 349636

Discussion

ESH eLearning, Faculty / Presenters, 349635

Health-Related Quality of Life (HRQoL) in CML-Patients at Diagnosis Compared to General Population

ESH eLearning, Marcel Lorch, 349634

The Effect of Comorbidities on Response Outcomes with First-Line Dasatinib Versus Imatinib in Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Post Hoc Analysis of DASISION

ESH eLearning, Massimo BRECCIA, 349633

Discussion

ESH eLearning, Faculty / Presenters, 349632

Keynote presentation: The role of patient reported outcomes in the management of patients with CML: Are we doing it right? Are we doing it enough?

ESH eLearning, Fabio Efficace, 349631

Introduction

ESH eLearning, Susanne Saussele, 349630

Discussion

ESH eLearning, Faculty / Presenters, 349629

The biology and implications of clonal hematopoiesis

ESH eLearning, Benjamin Ebert, 349628

Introduction

ESH eLearning, Tim Brümmendorf, 349627

Discussion

ESH eLearning, Faculty / Presenters, 349626

First Interim Results of the "Russian Prospective Study of Reduction and Discontinuation Treatment of TKI (READIT-2020)" in Patients with Chronic Myeloid Leukemia and Deep Molecular Response

ESH eLearning, Margarita Gurianova, 349625

Molecular Relapse after TKI Cessation for Treatment-Free Remission Can be Predicted By RNA-Sequencing

ESH eLearning, Vincent Alcazer, 349624

Discussion

ESH eLearning, Faculty / Presenters, 349623

Updated Results from Phase 1 Study of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI), in Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Patients Failing Prior TKI Therapies

ESH eLearning, Jorge Cortes, 349621

Mathematical Modelling of Immune Response in CML Patients Suggests Potential for TKI Reduction Prior to Cessation

ESH eLearning, Ingo Roeder, 349620

Optic Primary Analysis: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (PON)

ESH eLearning, Jorge Cortes, 349619

Discussion

ESH eLearning, Faculty / Presenters, 349618

Keynote presentation: The future of CML Therapy : Are more TKIs needed ?

ESH eLearning, Delphine Rea, 349617

Introduction

ESH eLearning, Franck Nicolini, 349616

Discussion

ESH eLearning, Faculty / Presenters, 349614

Special lecture 5: CML beyond TKI therapy

ESH eLearning, Giuseppe Saglio, 349613

Presentation

ESH eLearning, Robert Peter GALE, 349612

Discussion

ESH eLearning, Faculty / Presenters, 349611

Multimodal single-cell analysis delineates the evolution of myeloid leukemia

ESH eLearning, Peter van, 349610

Use of cutting-edge techniques

ESH eLearning, Greg Wang, 349609

Introduction

ESH eLearning, Faculty / Presenters, 349608

General Discussion

ESH eLearning, Faculty / Presenters, 349607

The role and outcome of stem cell transplant for blast phase CML

ESH eLearning, Aleksandar Radujkovic, 349606

Treatment of lymphoid in blast phase

ESH eLearning, Koji Sasaki, 349605

Treatment of myeloid in blast phase

ESH eLearning, Mhairi Copland, 349604

Challenges and controversies in the diagnosis and classification of blast phase CML"

ESH eLearning, Robert HASSERJIAN, 349603

Mutations, genetics, cytogenetics and their prognostic role in blast phase

ESH eLearning, Simona SOVERINI, 349602

Introductory overview - concepts and challenges

ESH eLearning, Rüdiger Hehlmann, 349601

Discussion

ESH eLearning, Faculty / Presenters, 349600

Janet Rowley Prize: Special lecture: BCR-ABL1 dependent and independent molecular factors that influence treatment outcome

ESH eLearning, Susan Branford, 349599

Janet Rowley Prize Presentation

ESH eLearning, Jerry Radich, 349598

Discussion

ESH eLearning, Faculty / Presenters, 349597

Leukemic Cytokines Co-Opt Regulatory T Cell and Th17 Immunity to Promote Disease Progression

ESH eLearning, Virginia Camacho, 349596

Perturbed Function of Natural Killer Cells By Inflammatory Cytokines in Chronic Myeloid Leukemia

ESH eLearning, Valeriya Kuznetsova, 349595

Discussion

ESH eLearning, Faculty / Presenters, 349593

The Lysophospholipid Metabolism Enzyme Gdpd3 Maintains Chronic Myelogenous Leukemia Stem Cells

ESH eLearning, Kazuhito Naka, 349592

Discussion

ESH eLearning, Faculty / Presenters, 349591

Keynote presentation: Evolution of our learning in stem cell

ESH eLearning, Ravi Bhatia, 349590

Introduction

ESH eLearning, Bing Carter, 349589

Discussion

ESH eLearning, Faculty / Presenters, 349588

Bcl2-mediated metabolic properties of leukemia stem cells

ESH eLearning, Craig Jordan, 349587

Introduction

ESH eLearning, Brian Huntly, 349586

Impact of Inhibition of Folate Metabolism in Leukaemic Stem Cells

ESH eLearning, Martha Zarou, 349585

Discussion

ESH eLearning, Faculty / Presenters, 349584

Detection and Targeting of Malignant Deaminase Activation in Chronic Myeloid Leukemia

ESH eLearning, Catriona Jamieson, 349583

Introduction

ESH eLearning, Tomasz Skorski, 349582

iCMLF - A Review

ESH eLearning, Tim P. Hughes, 349581

Does Ph+ in AML exist or not? vs CML

ESH eLearning, Catherine Smith, 349594

Discussion

ESH eLearning, Faculty / Presenters, 348394

The role of CAR T-cell therapy in cancer in 2030

ESH eLearning, Carl June, 348393

Introduction

ESH eLearning, Faculty / Presenters, 348392

Panel discussion

ESH eLearning, Faculty / Presenters, 348391

Perspectives: T-cell Non-Hodgkin’s Lymphoma

ESH eLearning, Paul Maciocia, 348390

Perspectives: Mantle Cell Lymphoma and Follicular Lymphoma

ESH eLearning, Marie José Kersten, 348389

Panel discussion

ESH eLearning, Faculty / Presenters, 348388

Case-based lecture: CAR-T for bridging to allogeneic transplant or repeated CARs?

ESH eLearning, Sara Ghorashian, 348387

Case-based lecture: CAR-T after allogeneic transplant

ESH eLearning, André Baruchel, 348386

Case-based lecture: CAR T-cell therapy in childhood ALL: what can we learn for adult patients?

ESH eLearning, Peter Bader, 348385

Discussion

ESH eLearning, Faculty / Presenters, 348384

CAR T-cells

ESH eLearning, Marie José Kersten, 348383

Bispecific antibodies

ESH eLearning, Martin Hutchings, 348382

Allo-transplant

ESH eLearning, Bertram Glass, 348381

Introduction

ESH eLearning, John G. Gribben, 348380

Panel discussion

ESH eLearning, Faculty / Presenters, 348379

Case-based lecture: Bispecifics in first line DLBCL?

ESH eLearning, Richard Greil, 348378

Case-based lecture: Bispecifics in relapsed DLBCL?

ESH eLearning, Stephan Schuster, 348377

Short Oral Presentation: Antitumor Activity and Safety Profile of Subcutaneous Epcoritamab in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: Dose-Escalation Data from the Epcore NHL-1 Trial

ESH eLearning, Pieternella Lugtenburg, 348376

Interactive case

ESH eLearning, Marion Subklewe, 348375

Live discussion

ESH eLearning, Faculty / Presenters, 348374

ESH eLearning, Faculty / Presenters, 348373

Discussion

ESH eLearning, Faculty / Presenters, 348372

CARs

ESH eLearning, Sham Mailankody, 348371

Bispecific antibodies

ESH eLearning, Hermann Einsele, 348370

Introduction

ESH eLearning, María-Victoria Mateos, 348369

Panel discussion

ESH eLearning, Faculty / Presenters, 348368

Interactive case: Multiple Myeloma

ESH eLearning, María-Victoria Mateos, 348367

Short Oral Presentation: Teclistamab and Talquetamab Modulate Levels of Soluble B-Cell Maturation Antigen in Patients with Relapsed and/or Refractory Multiple Myeloma

ESH eLearning, Suzette Girgis, 348366

Short Oral Presentation: Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy, in Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results from Cartitude-1

ESH eLearning, Saad Z. Usmani, 348365

Case-based lecture: BCMA targeted CAR T-cell therapy for multiple r/r MM

ESH eLearning, Sham Mailankody, 348364

Short Oral Presentation: Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) × CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results of a Phase 1, First-in-Human Study

ESH eLearning, Niels W.C.J. van de Donk, 348363

Interactive case: Multiple Myeloma

ESH eLearning, María-Victoria Mateos, 348362

Panel discussion

ESH eLearning, Faculty / Presenters, 348361

Perspectives: Learning from doing?

ESH eLearning, Christian Chabannon, 348360

Case-based lecture: Hematotoxicity: early & late Cytopenia and Hypogammaglobulinaemia

ESH eLearning, Marion Subklewe, 348359

Case-based lecture: Novel strategies to prevent/treat CRS/ICANS

ESH eLearning, Stephan Grupp, 348358